ONCOLOGY

SN should be the standard of care in this population.

There is no established standard of care after first-line therapy for metastatic esophageal cancer.

Nivolumab is the first PD-1 inhibitor to show benefit in this population and could be a new potential standard therapy.

Pembrolizumab with chemo yielded better survival, response rates vs chemo with placebo.

Nivolumab plus chemotherapy has superior survival effect vs chemotherapy alone.

Patients may need counseling about medical and nutritional interventions.

Staging the patient’s physiological state using derivative SIR biomarkers is important.

Delivering oesophago-gastric cancer care during the COVID-19 pandemic at a high-volume tertiary centre in the UK

Findings from a multicenter, randomized controlled trial.

A cell-collection device that can be used in primary care.

Findings from a phase 2B RCT.

Less toxicity in esophageal cancer.

Does local tumour response translate to survival benefit?

Lung, breast, colorectal, esophageal cancer deaths are all expected to rise.